Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
- DOI
- 10.1016/j.esmoop.2023.101580
- Published
- 2023 Aug
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2023.101580,
title = {Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.},
author = {Garon EB and Reck M and Nishio K and Heymach JV and Nishio M and Novello S and Paz-Ares L and Popat S and Aix SP and Graham H and Butts BD and Visseren-Grul C and Nakagawa K and RELAY study investigators},
year = {2023},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2023.101580},
url = {https://doi.org/10.1016/j.esmoop.2023.101580}
}RIS
TY - JOUR TI - Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. AU - Garon EB AU - Reck M AU - Nishio K AU - Heymach JV AU - Nishio M AU - Novello S AU - Paz-Ares L AU - Popat S AU - Aix SP AU - Graham H AU - Butts BD AU - Visseren-Grul C AU - Nakagawa K AU - RELAY study investigators PY - 2023 JO - ESMO open DO - 10.1016/j.esmoop.2023.101580 UR - https://doi.org/10.1016/j.esmoop.2023.101580 ER -
APA
EB, G., M, R., K, N., JV, H., M, N., S, N., L, P., S, P., SP, A., H, G., BD, B., C, V., K, N., & investigators, R. S. (2023). Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.. ESMO open. https://doi.org/10.1016/j.esmoop.2023.101580
Source records
- pubmed · retrieved 2026-09-26T17:12:38.839Z